The FDA, in accordance with its approval process as described above, has opened the door for the first product of its kind to hit the market. On July 9, the FDA approved Novartis’ new patch to help treat Alzheimer’s Disease and Parkinson’s Disease, two terribly debilitating medical conditions that have recently been treated with pills. The story was reported on CNN.
The patch is meant to last for 24 hours and will allow patients to not have to remember to take their medication, much like patches that have been approved for other medical conditions. Although the patch comes with a high degree of promise, its release is not expected to boost sales for Novartis by any appreciable amount.
"It's good for Alzheimer's because you don't have to remember to take your pill," said Les Funtleyder, analyst for Miller Tabak. But he said that Exelon is not a big seller for Novartis, and offering up a patch in addition to a pill is unlikely to significantly boost sales.